Dare Bioscience Inc (DARE)is dedicated to the development of innovative products in women’s health. The company stock was up 31.36% to $3.1 in the after-market session.
What they do…
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The company’s mission is to identify, develop and market a diverse portfolio of differentiated therapies for women, mainly in the areas of contraception, vaginal health, sexual health, and fertility.
- Top 3 Cloud Computing Stocks to Watch For in 2021
- 3 Best Work-From-Home Stocks for Long-term Investment
While the latest rally in the Corporate Universe stock is extremely impressive, nothing material related to the company’s business was announced that could have prompted such a move. Thus, it could be necessary to see something that took place in a recent couple of months.
January 05, 2021, Daré Bioscience Inc., a pioneer in research in women’s health (NASDAQ: DARE), announced that its Founder and Chief Executive Officer, Sabrina Martucci Johnson, is engaging in a fireside chat at the H.C. Wainwright Interactive Conference BIOCONNECT 2021 on 11-14 January 2021.
December 7, 2020, DARE-BVFREE phase 3 randomised, double aveugled, placebo-controlled clinical trial assessment of DARE-BV1 among 307 women afflicted with bacterial vaginosis, a severe disease projected to affect approximately 21 million females in the United States, was disclosed by Daré Bioscience, Inc. (NASDAQ: DARE). DARE-BV1 is a research thermosetting bioadhesive hydrogel containing clindamycin phosphate 2 percent and is intended to be used as an easy, one-time vaginal bacterial vaginosis treatment. The trial found its primary outcome that a single DARE-BV1 administration was superior to placebo as the key clinical tool for bacterial vaginosis diagnosed women.